^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Kidney Cancer

    Related cancers:
    1d
    CAIX-targeted PET/CT in the evaluation of clear cell renal cell carcinoma: a head-to-head comparison with [18F]FDG PET/CT. (PubMed, Eur J Nucl Med Mol Imaging)
    [18F]AlF-NYM005 PET/CT was superior to [18F]FDG in the detection of renal tumours and metastatic lesions, demonstrating higher radiotracer uptake and more accurate staging.
    Journal • Head-to-Head
    |
    CA9 (Carbonic anhydrase 9)
    1d
    Integration of network toxicology and bioinformatics identifies key targets and pathways in 1,3-butadiene-induced nephrotoxicity. (PubMed, Int J Environ Health Res)
    Additionally, using the TCGA database, we found that these targets have diagnostic and prognostic significance in renal cancer. Our findings suggest that BCL2, CASP3, MMP9, SIRT1, and TNF may play crucial roles in both nephrotoxicity and renal cancer progression, offering new insights into the molecular mechanisms of 1,3-BD-induced renal injury and potential intervention targets.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • CASP3 (Caspase 3) • MMP9 (Matrix metallopeptidase 9) • SIRT1 (Sirtuin 1)
    1d
    Cell-free DNA epigenomic profiling enables noninvasive detection and monitoring of translocation renal cell carcinoma. (PubMed, J Clin Invest)
    By defining a TFE3-driven epigenomic signature in tRCC cell lines and detecting it in patient plasma using ChIP-seq, we distinguished tRCC from clear-cell RCC (AUC = 0.86) and samples of individuals without evidence of cancer (AUC = 0.92) at low tumor fractions (<1%). This work establishes a framework for noninvasive epigenomic detection, diagnosis, and monitoring of tRCC, with implications for other mutationally quiet, fusion-driven cancers.
    Journal
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    1d
    Next-generation liquid biopsies: detecting circulating epigenetic changes to identify translocation renal cell carcinoma. (PubMed, J Clin Invest)
    may enable disease monitoring and subtype classification in other genetically quiet tumors. Epigenomic liquid biopsy is a promising framework to improve diagnostic accuracy and guide personalized management for tRCC.
    Journal • Liquid biopsy
    |
    TFE3 (Transcription Factor Binding To IGHM Enhancer 3)
    3d
    Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial (clinicaltrials.gov)
    P2, N=180, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: Jan 2026 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • everolimus • pazopanib
    4d
    Study on the Role and Molecular Mechanism of HKDC1 in Regulating PD - L1 - Mediated Renal Cancer Immune Evasion by Activating STAT1 in Tumor Cells (ChiCTR2600116467)
    P=N/A, N=50, Not yet recruiting, The First Hospital of Jiaxing; The First Hospital of Jiaxing
    New trial
    |
    PD-L1 (Programmed death ligand 1)
    4d
    Diagnostic Performance of RenalPath in Renal Carcinoma: A Prospective, Multicenter, Observational Validation Study (ChiCTR2600116157)
    P=N/A, N=0, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    4d
    Deep Feature Matching of CT Images for Predicting Pathological Indices in Renal Cell Carcinoma: A Multicenter Prospective Observational Study (ChiCTR2500115538)
    P=N/A, N=0, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    4d
    A Multicenter, Prospective, Observational Study Evaluating the Accuracy of the Multimodal Foundation Model Renal-FM in Renal Cancer Imaging and Pathological Diagnosis (ChiCTR2500114906)
    P=N/A, N=600, Not yet recruiting, Zhongshan Hospital, Fudan University; Zhongshan Hospital, Fudan University
    New trial
    4d
    Development of an AI-Based Multimodal Model for the Diagnosis and Treatment of Metastatic Renal Cell Carcinoma (ChiCTR2500114795)
    P=N/A, N=25000, Not yet recruiting, Renji Hospital, Shanghai Jiaotong University School of Medicine; Renji Hospital, Shanghai Jiaotong University School of Medicine
    New trial
    4d
    Demonstration Clinical cohort Construction Project - Renal Cancer (ChiCTR2500114204)
    P=N/A, N=1000, Recruiting, Renji Hospital affiliated to Shanghai Jiaotong University School of Medicine; Renji Hospital affiliated to Shanghai Jiaotong University School of Medi
    New trial
    4d
    An observational study of the use of a urine amino acid test in the screening of a healthy population and in the early diagnosis and prognostic management of patients with urologic disorders (ChiCTR2500112658)
    P=N/A, N=500, Not yet recruiting, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
    New trial